Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1193 clinical trials
Featured trial
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (202200050434)

Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of combination therapies with adagrasib in patients with advanced NSCLC with TPS ≥ 1% and KRAS G12C mutation

pembrolizumab
KRAS
  • 38 views
  • 20 Dec, 2022
  • 24 locations
Featured trial
  • 25 views
  • 19 Dec, 2022
  • 120 locations
Featured trial
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder …

measurable disease
cancer
bladder tumor
cancer of the ovary
  • 46 views
  • 11 Jul, 2022
  • 19 locations
Featured trial
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)  

progression free survival (PFS) when compared to docetaxel in participants with metastatic non-squamous non-small-cell lung cancer (NSCLC) expressing CEACAM5 greater than or equal to 2+ in intensity in at

  • 180 views
  • 02 Feb, 2023
  • 5 locations
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT 210) (FIGHT-210)

This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options

measurable disease
lung carcinoma
metastasis
FGFR1
  • 0 views
  • 28 Oct, 2022
  • 17 locations
Featured trial
Non-Small Cell Lung Cancer Research Study from Home

At Sanguine, we are accelerating medicine with the help of volunteers like you. You can contribute to the development of new treatments and help advance Non-Small Cell Lung Cancer research with

lung carcinoma
  • 0 views
  • 01 Dec, 2022
  • 1 location
Featured trial
Small cell lung cancer (SCLC) Receiving Zepzelca

People with SMALL CELL LUNG CANCER are asked to participate in a research study being conducted by Montefiore Medical Center.

lung carcinoma
  • 3 views
  • 06 Aug, 2021
  • 1 location
Featured trial
EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

-3475) in subjects previously untreated for their advance or metastatic intrathoracic, PD-L1 positive (TPS≥1% [tumor proportion score]) non-small cell lung cancer (NSCLC).

  • 0 views
  • 29 Nov, 2022
  • 1 location
Featured trial
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

refractory non-small cell lung cancer
lung cancer
advanced lung cancer
lung metastases
recurrent non-small cell lung cancer
  • 37 views
  • 27 Dec, 2022
  • 202 locations
Featured trial
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …

platinum-based chemotherapy
lung cancer
advanced lung cancer
experimental drug
cancer
  • 543 views
  • 04 May, 2022
  • 143 locations